{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:53:09Z","timestamp":1789606389539,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P01CA221757"],"award-info":[{"award-number":["P01CA221757"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01 CA233899"],"award-info":[{"award-number":["R01 CA233899"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P50CA221745"],"award-info":[{"award-number":["P50CA221745"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.modpat.2024.100557","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T12:40:22Z","timestamp":1719924022000},"page":"100557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell\/Neuroendocrine Carcinoma With Prognostic Implications"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-9667","authenticated-orcid":false,"given":"Dilara","family":"Akbulut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Yuen","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze Gokturk","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Basar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Rammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Sarungbam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Bei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Gopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson W.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish K.","family":"Tickoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Baine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard H.","family":"Bochner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene J.","family":"Pietzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean F.","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopa","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Rekhtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ostrovnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2938-6627","authenticated-orcid":false,"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.modpat.2024.100557_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12022-016-9444-5","article-title":"Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization classification: molecular and clinical characteristics","volume":"27","author":"Kouba","year":"2016","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.modpat.2024.100557_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12885-015-1188-y","article-title":"A\u00a0population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992-2010","volume":"15","author":"Dores","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.modpat.2024.100557_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clgc.2022.05.005","article-title":"Long-term outcomes of local and metastatic small cell carcinoma of the urinary bladder and genomic analysis of patients treated with neoadjuvant chemotherapy","volume":"20","author":"Teo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2024.100557_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2012.04.020","article-title":"Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center","volume":"64","author":"Lynch","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.modpat.2024.100557_bib5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/cam4.3699","article-title":"A\u00a0phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract","volume":"10","author":"Sarfaty","year":"2021","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.modpat.2024.100557_bib6","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","article-title":"Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis","volume":"24","author":"Chang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.modpat.2024.100557_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.modpat.2024.100557_bib8","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2024.100557_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2023.05.023","article-title":"Identification of lineage-specific transcriptional factor-defined molecular subtypes in small cell bladder cancer","volume":"85","author":"Feng","year":"2024","journal-title":"Eur Urol"},{"issue":"6627","key":"10.1016\/j.modpat.2024.100557_bib10","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/386852a0","article-title":"An achaete-scute homologue essential for neuroendocrine differentiation in the lung","volume":"386","author":"Borges","year":"1997","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.modpat.2024.100557_bib11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.celrep.2016.06.081","article-title":"ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs","volume":"16","author":"Borromeo","year":"2016","journal-title":"Cell Rep"},{"issue":"30","key":"10.1016\/j.modpat.2024.100557_bib12","doi-asserted-by":"crossref","first-page":"21160","DOI":"10.1074\/jbc.M708692200","article-title":"Targeted disruption of NeuroD, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung","volume":"283","author":"Neptune","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"13-14","key":"10.1016\/j.modpat.2024.100557_bib13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gad.314815.118","article-title":"POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer","volume":"32","author":"Huang","year":"2018","journal-title":"Genes Dev"},{"issue":"12","key":"10.1016\/j.modpat.2024.100557_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189340","article-title":"Skn-1a\/Pou2f3 functions as a master regulator to generate Trpm5-expressing chemosensory cells in mice","volume":"12","author":"Yamashita","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.modpat.2024.100557_bib15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.modpat.2024.100557_bib16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jtho.2022.06.004","article-title":"POU2F3 in SCLC: clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC","volume":"17","author":"Baine","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2024.100557_bib17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41419-023-06053-y","article-title":"YAP1 expression is associated with survival and immunosuppression in small cell lung cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Cell Death Dis"},{"issue":"11","key":"10.1016\/j.modpat.2024.100557_bib18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","article-title":"Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer","volume":"39","author":"Chan","year":"2021","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.modpat.2024.100557_bib19","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","article-title":"DLL3 as an emerging target for the treatment of neuroendocrine neoplasms","volume":"27","author":"Yao","year":"2022","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.modpat.2024.100557_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"issue":"6","key":"10.1016\/j.modpat.2024.100557_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.modpat.2024.100557_bib22","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2024.100557_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2022.07.003","article-title":"Urothelial carcinoma: divergent differentiation and morphologic subtypes","volume":"15","author":"Gandhi","year":"2022","journal-title":"Surg Pathol Clin"},{"issue":"suppl 1","key":"10.1016\/j.modpat.2024.100557_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","article-title":"Lung neuroendocrine neoplasms: recent progress and persistent challenges","volume":"35","author":"Rekhtman","year":"2022","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100557_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/tlcr.2018.02.02","article-title":"Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"10.1016\/j.modpat.2024.100557_bib26","first-page":"2913","article-title":"Establishment and identification of small cell lung cancer cell lines having classic and variant features","volume":"45","author":"Carney","year":"1985","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.modpat.2024.100557_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007343","article-title":"Systems-level network modeling of small cell lung cancer subtypes identifies master regulators and destabilizers","volume":"15","author":"Wooten","year":"2019","journal-title":"PLoS Comput Biol"},{"issue":"43","key":"10.1016\/j.modpat.2024.100557_bib28","doi-asserted-by":"crossref","first-page":"73745","DOI":"10.18632\/oncotarget.20572","article-title":"Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer","volume":"8","author":"McColl","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.modpat.2024.100557_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101201","article-title":"Urothelial-to-neural plasticity drives progression to small cell bladder cancer","volume":"23","author":"Yang","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.modpat.2024.100557_bib30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100557_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","article-title":"MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate","volume":"38","author":"Ireland","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.modpat.2024.100557_bib32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s43018-020-0046-2","article-title":"A\u00a0biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity","volume":"1","author":"Simpson","year":"2020","journal-title":"Nat Cancer"},{"issue":"10","key":"10.1016\/j.modpat.2024.100557_bib33","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/cas.13013","article-title":"Loss of YAP1 defines neuroendocrine differentiation of lung tumors","volume":"107","author":"Ito","year":"2016","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.modpat.2024.100557_bib34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/path.5781","article-title":"Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer","volume":"255","author":"Asrani","year":"2021","journal-title":"J\u00a0Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2024.100557_bib35","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.jtho.2020.07.008","article-title":"The rare YAP1 subtype of SCLC revisited in a biobank of 39 circulating tumor cell patient derived explant models: a brief report","volume":"15","author":"Pearsall","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2024.100557_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw122","article-title":"Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression","volume":"108","author":"Polley","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.modpat.2024.100557_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240973","article-title":"The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy","volume":"15","author":"Tendler","year":"2020","journal-title":"PLoS One"},{"issue":"484","key":"10.1016\/j.modpat.2024.100557_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.modpat.2024.100557_bib39","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.5858\/arpa.2018-0497-OA","article-title":"Delta-like protein 3 prevalence in small cell lung cancer and DLL3 (SP347) assay characteristics","volume":"143","author":"Huang","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.modpat.2024.100557_bib40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2019.10.010","article-title":"DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile","volume":"138","author":"Hermans","year":"2019","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2024.100557_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12022-020-09657-8","article-title":"Diagnostic and predictive role of DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms","volume":"32","author":"Liverani","year":"2021","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100557_bib42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/1078-0432.CCR-18-1278","article-title":"Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target","volume":"25","author":"Koshkin","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.modpat.2024.100557_bib43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/PAI.0000000000000884","article-title":"Molecular profiling reveals limited targetable biomarkers in neuroendocrine carcinoma of the cervix","volume":"29","author":"Cimic","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100557_bib44","first-page":"53","article-title":"Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma","volume":"16","author":"Song","year":"2018","journal-title":"Exp Ther Med"},{"issue":"3","key":"10.1016\/j.modpat.2024.100557_bib45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1530\/EC-20-0611","article-title":"DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas","volume":"10","author":"Ingenwerth","year":"2021","journal-title":"Endocr Connect"},{"issue":"15_suppl","key":"10.1016\/j.modpat.2024.100557_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5100","article-title":"Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC)","volume":"39","author":"Aggarwal","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100557_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.modpat.2024.100557_bib48","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2024.100557_bib49","first-page":"74","article-title":"A\u00a0phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors","volume":"5","author":"Mansfield","year":"2021","journal-title":"NPJ\u00a0Precis Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2024.100557_bib50","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"302","key":"10.1016\/j.modpat.2024.100557_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A\u00a0DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in\u00a0vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.modpat.2024.100557_bib52","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.2147\/OTT.S244860","article-title":"The role of DLLs in cancer: a novel therapeutic target","volume":"13","author":"Xiu","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.modpat.2024.100557_bib53","article-title":"Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse","volume":"3","author":"Dylla","year":"2016","journal-title":"Mol Cell Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2024.100557_bib54","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.modpat.2024.100557_bib55","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","article-title":"ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224001376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224001376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:17:02Z","timestamp":1759349822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395224001376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0893395224001376"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100557","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell\/Neuroendocrine Carcinoma With Prognostic Implications","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100557"}}